DK0910400T3 - Terapier for kronisk nyresvigt - Google Patents

Terapier for kronisk nyresvigt

Info

Publication number
DK0910400T3
DK0910400T3 DK97923567T DK97923567T DK0910400T3 DK 0910400 T3 DK0910400 T3 DK 0910400T3 DK 97923567 T DK97923567 T DK 97923567T DK 97923567 T DK97923567 T DK 97923567T DK 0910400 T3 DK0910400 T3 DK 0910400T3
Authority
DK
Denmark
Prior art keywords
chronic kidney
kidney failure
risk
treatment
failure therapies
Prior art date
Application number
DK97923567T
Other languages
Danish (da)
English (en)
Inventor
Kuber T Sampath
Charles M Cohen
Original Assignee
Curis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curis Inc filed Critical Curis Inc
Application granted granted Critical
Publication of DK0910400T3 publication Critical patent/DK0910400T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK97923567T 1996-05-06 1997-05-06 Terapier for kronisk nyresvigt DK0910400T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/643,321 US6498142B1 (en) 1996-05-06 1996-05-06 Morphogen treatment for chronic renal failure
PCT/US1997/007655 WO1997041880A1 (en) 1996-05-06 1997-05-06 Therapies for chronic renal failure

Publications (1)

Publication Number Publication Date
DK0910400T3 true DK0910400T3 (da) 2003-11-24

Family

ID=24580305

Family Applications (2)

Application Number Title Priority Date Filing Date
DK97922726T DK0914146T3 (da) 1996-05-06 1997-05-06 Morfogenbehandling af kronisk nyresvigt
DK97923567T DK0910400T3 (da) 1996-05-06 1997-05-06 Terapier for kronisk nyresvigt

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK97922726T DK0914146T3 (da) 1996-05-06 1997-05-06 Morfogenbehandling af kronisk nyresvigt

Country Status (11)

Country Link
US (5) US6498142B1 (de)
EP (2) EP0914146B1 (de)
JP (4) JP4766722B2 (de)
AT (2) ATE245997T1 (de)
AU (2) AU2832297A (de)
CA (2) CA2254954C (de)
DE (2) DE69723845T2 (de)
DK (2) DK0914146T3 (de)
ES (2) ES2230604T3 (de)
PT (2) PT910400E (de)
WO (2) WO1997041880A1 (de)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077823A (en) * 1991-03-11 2000-06-20 Creative Biomolecules, Inc. Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury
CA2363965C (en) * 1991-03-11 2010-05-18 Curis, Inc. Protein-induced morphogenesis
US20030167492A1 (en) 1994-07-08 2003-09-04 Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a gdf-11 dominant negative polypeptide, and methods of making and using same
US6498142B1 (en) * 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
ATE278414T1 (de) 1997-05-05 2004-10-15 Curis Inc Therapien zur behandlung von akutem nierenversagen
AU7473098A (en) * 1997-05-07 1998-11-27 Biogen, Inc. Novel therapies for cystic kidney disease
ATE220564T1 (de) 1997-08-14 2002-08-15 Sulzer Innotec Ag Zusammensetzung und vorrichtung zur reparatur von knorpelgewebe in vivo bestehend aus nanokapseln mit osteoinduktiven und/oder chondroinduktiven faktoren
US6203788B1 (en) * 1997-09-29 2001-03-20 Adherex Inc. Compounds and methods for regulating cell adhesion
EP1037910A2 (de) * 1997-12-04 2000-09-27 Curis, Inc. Nachschutz der glatte muskulatur durch morphogenetische protein
BR9912548A (pt) * 1998-07-28 2002-01-29 Univ Johns Hopkins Med Fator-11 de diferenciação de crescimento
US7087577B2 (en) * 1998-10-16 2006-08-08 Zimmer Orthobiologies, Inc. Method of promoting natural bypass
US6992066B2 (en) 1998-10-16 2006-01-31 Zimmer Orthobiologics, Inc. Povidone-containing carriers for polypeptide growth factors
JP4975922B2 (ja) * 1999-09-14 2012-07-11 バイオジェン・アイデック・エムエイ・インコーポレイテッド １つ以上のインテグリンアンタゴニストを使用する慢性腎不全の治療
US20020173453A1 (en) * 2000-12-15 2002-11-21 Rama Akella Method of treating renal injury
US7763769B2 (en) 2001-02-16 2010-07-27 Kci Licensing, Inc. Biocompatible wound dressing
US7700819B2 (en) 2001-02-16 2010-04-20 Kci Licensing, Inc. Biocompatible wound dressing
US7232802B2 (en) * 2001-12-21 2007-06-19 Zimmer Orthobiologics, Inc. Compositions and methods for promoting myocardial and peripheral angiogenesis
US7622562B2 (en) 2002-06-26 2009-11-24 Zimmer Orthobiologics, Inc. Rapid isolation of osteoinductive protein mixtures from mammalian bone tissue
JP2006516020A (ja) * 2002-08-28 2006-06-15 キュリス インコーポレイテッド 慢性腎不全の治療におけるモルフォゲン及びａｃｅ阻害薬の共投与
EP2441474B1 (de) 2003-10-17 2015-08-05 Joslin Diabetes Center, Inc. Verfahren und Zusammensetzungen zur Modulation der Adipozytfunktion
US7844367B2 (en) 2003-12-23 2010-11-30 Rain Bird Corporation Code replacement for irrigation controllers
JP4964122B2 (ja) * 2004-03-30 2012-06-27 レリプサ， インコーポレイテッド イオン結合組成物
JP2008500816A (ja) * 2004-03-31 2008-01-17 ゼンコー・インコーポレイテッド 改善された性質を有するｂｍｐ−７変異体
WO2006130690A2 (en) * 2005-06-01 2006-12-07 Joslin Diabetes Center, Inc. Methods and compositions for inducing brown adipogenesis
US7771995B2 (en) * 2005-11-14 2010-08-10 Merial Limited Plasmid encoding human BMP-7
EP3536704B1 (de) 2005-11-14 2021-08-25 Boehringer Ingelheim Animal Health USA Inc. Gentherapie für nierenversagen
US20090004159A1 (en) * 2006-01-24 2009-01-01 The Board Of Trustees Of The University Of Illinoi Polymerized Hemoglobin Media and Its Use in Isolation and Transplantation of Islet Cells
WO2007087570A2 (en) * 2006-01-24 2007-08-02 Northfield Laboratories, Inc. Polymerized hemoglobin media and its use in isolation and transplantation of islet cells
US20080090765A1 (en) * 2006-05-25 2008-04-17 The Trustees Of Columbia University In The City Of New York Compositions for modulating growth of embryonic and adult kidney tissue and uses for treating kidney damage
WO2007137584A1 (en) 2006-05-30 2007-12-06 Antibodyshop A/S Methods and devices for rapid assessment of severity of injury
US7722665B2 (en) * 2006-07-07 2010-05-25 Graft Technologies, Inc. System and method for providing a graft in a vascular environment
EP2574625B1 (de) * 2006-07-21 2015-02-25 HuBit genomix, Inc. Mittel zur Behandlung von Nierenerkrankungen
WO2008075173A2 (en) * 2006-12-15 2008-06-26 Ruprecht-Karls-Universität Heidelberg Methods for treating podocyte-related disorders
AU2008245900B2 (en) * 2007-04-24 2013-07-25 Advanced Technologies And Regenerative Medicine, Llc Engineered renal tissue
DE102007034580B4 (de) * 2007-07-13 2012-11-08 NMI Naturwissenschaftliches und Medizinisches Institut an der Universität Tübingen Biomaterial basierend auf einem hydrophilen polymeren Träger
US20090155245A1 (en) * 2007-12-18 2009-06-18 Fang Carrie H Treatment for Organ Regeneration with Combination of Drug and Biologics
JP2011523357A (ja) * 2008-05-06 2011-08-11 ジョスリン ダイアビーティス センター インコーポレイテッド 褐色脂肪細胞分化を誘導するための方法および組成物
WO2009157165A1 (ja) * 2008-06-24 2009-12-30 株式会社根本杏林堂 薬液注入装置、この薬液注入装置を有する透視撮像システム、薬液注入装置のコンピュータプログラムおよびデータ処理方法
CN105067819B (zh) * 2008-08-28 2018-05-22 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
EP2324354B1 (de) * 2008-08-29 2014-07-16 Astute Medical, Inc. Verfahren zur prognose von akuter niereninsuffizienz
CN104399089B (zh) * 2008-10-21 2017-04-19 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
CA2740923A1 (en) * 2008-10-21 2010-04-29 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2361018B1 (de) 2008-11-10 2015-04-01 Astute Medical, Inc. Verfahren und zusammensetzungen für die diagnose und prognose von nierenschädigung und nierenversagen
KR20110097850A (ko) * 2008-11-22 2011-08-31 아스튜트 메디컬 인코포레이티드 신손상 및 신부전의 진단 및 예후 예측을 위한 방법 및 조성물
EP2393937A4 (de) * 2009-02-06 2012-08-08 Astute Medical Inc Verfahren und zusammensetzungen zur diagnose und prognose von nierenverletzungen und niereninsuffizienz
US9229010B2 (en) 2009-02-06 2016-01-05 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
SG2014010680A (en) * 2009-02-12 2014-04-28 Stryker Corp Peripheral administration of proteins including tgf-beta superfamily members for treatment of systemic disorders and disease
EP2396026A2 (de) * 2009-02-12 2011-12-21 Stryker Corporation Zusammensetzungen und verfahren für die minimal invasive systemische abgabe von proteinen einschliesslich mitglieder der tgf-superfamilie
US8828937B2 (en) * 2009-03-12 2014-09-09 Haase Investments Ug Bone morphogenetic protein 2 (BMP2) variants with reduced BMP antagonist sensitivity
WO2010144696A1 (en) 2009-06-11 2010-12-16 Burnham Institute For Medical Research Directed differentiation of stem cells
EA201290056A1 (ru) 2009-08-07 2012-08-30 Астьют Медикал, Инк. Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
ES2387379T3 (es) 2009-09-17 2012-09-21 Stryker Corporation Tampones para controlar el pH de las proteínas morfogenéticas óseas
NZ628085A (en) 2009-11-07 2015-12-24 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP5763098B2 (ja) 2009-12-20 2015-08-12 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
CN102822197A (zh) 2009-12-22 2012-12-12 史赛克公司 具有降低的免疫原性的bmp-7变体
NZ700695A (en) 2010-02-05 2016-05-27 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CA2790785A1 (en) 2010-02-26 2011-09-01 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
ES2667066T3 (es) 2010-05-24 2018-05-09 The Trustees Of Columbia University In The City Of New York Proteínas NGAL mutantes y usos de las mismas
CA2803498A1 (en) 2010-06-23 2011-12-29 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2011269775B2 (en) 2010-06-23 2015-01-15 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
KR101767860B1 (ko) 2010-08-20 2017-08-14 와이어쓰 엘엘씨 디자이너 골형성 단백질
US9688735B2 (en) 2010-08-20 2017-06-27 Wyeth Llc Designer osteogenic proteins
EP3540440B1 (de) 2011-12-08 2022-09-28 Astute Medical, Inc. Verfahren und verwendungen zur bewertung von nierenschäden und nierenstatus
EP2916851A2 (de) 2012-10-08 2015-09-16 Relypsa, Inc. Kaliumbindendes mittel zur behandlung von bluthochdruck und hyperkaliämie
WO2014081980A2 (en) 2012-11-21 2014-05-30 The Trustees Of Columbia University In The City Of New York Mutant ngal proteins and uses thereof
CA2898581C (en) 2013-01-17 2022-07-05 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US8945872B2 (en) 2013-01-25 2015-02-03 Warsaw Orthopedic, Inc. Methods of purifying human recombinant growth and differentiation factor-5 (rhGDF-5) protein
US9169308B2 (en) 2013-01-25 2015-10-27 Warsaw Orthopedic, Inc. Methods and compositions of human recombinant growth and differentiation factor-5 (rhGDF-5) isolated from inclusion bodies
US9359417B2 (en) 2013-01-25 2016-06-07 Warsaw Orthopedic, Inc. Cell cultures and methods of human recombinant growth and differentiaton factor-5 (rhGDF-5)
US9051389B2 (en) 2013-01-25 2015-06-09 Warsaw Orthopedic, Inc. Expression conditions and methods of human recombinant growth and differentiation factor-5 (rhGDF-5)
US8956829B2 (en) 2013-01-25 2015-02-17 Warsaw Orthopedic, Inc. Human recombinant growth and differentiaton factor-5 (rhGDF-5)
EP2784083A1 (de) 2013-03-28 2014-10-01 Charité - Universitätsmedizin Berlin Knochenmorphogenetische Protein (BMP)-Varianten mit hoch reduzierter Antagonisten-Sensibilität und erweiterter spezifischer biologischer Aktivität
US10539588B2 (en) * 2013-11-11 2020-01-21 General Electric Company Method for reducing error in rotor speed measurements
EP2944326B1 (de) 2014-05-16 2018-11-21 Cyanagen Srl Tricarbocyanin-cyclodextrin-konjugate und deren verwendung zur diagnose von nierenkrankheiten
EP3543339A1 (de) 2015-02-13 2019-09-25 Factor Bioscience Inc. Nukleinsäureprodukte und verabreichungsverfahren dafür
AU2017277305A1 (en) 2016-06-06 2018-12-20 Astute Medical, Inc. Management of acute kidney injury using insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2
AU2017312113B2 (en) 2016-08-17 2023-05-25 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
JP2019039673A (ja) * 2017-08-22 2019-03-14 セイコーエプソン株式会社 時間デジタル変換回路、回路装置、物理量測定装置、電子機器及び移動体

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1156741B (it) * 1978-05-15 1987-02-04 Sigma Tau Ind Farmaceuti Applicazione terapeutica della carnitina e di alcuni derivati acilati della carnitina nell'emodialisi
US4342828A (en) 1979-07-20 1982-08-03 Morinaga Milk Industry Co., Ltd. Method for producing substance capable of stimulating differentiation and proliferation of human granulopoietic stem cells
US4627839A (en) * 1985-11-21 1986-12-09 American Hospital Supply Corporation Patient controlled analgesia conversion
US5013649A (en) * 1986-07-01 1991-05-07 Genetics Institute, Inc. DNA sequences encoding osteoinductive products
IL83003A (en) 1986-07-01 1995-07-31 Genetics Inst Factors that soak bone formation
US5011691A (en) * 1988-08-15 1991-04-30 Stryker Corporation Osteogenic devices
US5266683A (en) * 1988-04-08 1993-11-30 Stryker Corporation Osteogenic proteins
US5045452A (en) * 1988-09-02 1991-09-03 Brigham And Women's Hospital Method for evaluating nephrotoxicity
ES2113857T3 (es) 1989-03-28 1998-05-16 Genetics Inst Composiciones osteoinductoras.
CA2082941A1 (en) 1990-05-16 1991-11-17 Rodney M. Hewick Bone and cartilage inductive proteins
JPH0426624A (ja) * 1990-05-18 1992-01-29 Tsumura & Co 慢性腎不全改善剤
DE69123582T2 (de) 1990-06-22 1997-05-15 E.I. Du Pont De Nemours & Co., Wilmington, Del. Behandlung des chronischen nierenversagens mit imidazol-angiotensin-ii-rezeptorantagonisten
US6194376B1 (en) * 1991-03-11 2001-02-27 Creative Biomolecules, Inc. Method for modulating inflammatory response comprising administering morphogen
US5849686A (en) * 1991-03-11 1998-12-15 Creative Biomolecules, Inc. Morphogen-induced liver regeneration
CA2363965C (en) * 1991-03-11 2010-05-18 Curis, Inc. Protein-induced morphogenesis
ATE203166T1 (de) 1991-03-11 2001-08-15 Curis Inc Protein-induzierende morphogenese
US6077823A (en) * 1991-03-11 2000-06-20 Creative Biomolecules, Inc. Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury
US7056882B2 (en) * 1991-03-11 2006-06-06 Curis, Inc. Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases
US6287816B1 (en) 1991-06-25 2001-09-11 Genetics Institute, Inc. BMP-9 compositions
JP3616089B2 (ja) 1991-08-30 2005-02-02 キュリス インコーポレイテッド 形態形成誘導蛋白のスクリーニング方法
WO1993005751A2 (en) 1991-08-30 1993-04-01 Creative Biomolecules, Inc. Osteogenic proteins in the treatment of bone deseases
EP0601106B2 (de) 1991-08-30 2003-11-05 Curis, Inc. Morphogen-induzierte Modulation von entzündlichen Antworten
US6120760A (en) * 1992-02-12 2000-09-19 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Growth/differentiation factors of the TGF-β family
CA2141555C (en) 1992-07-31 2007-03-27 William K. Jones Morphogenic protein soluble complex and composition thereof
DE69333040T3 (de) 1992-07-31 2007-10-11 Curis, Inc., Cambridge Morphogen induzierte nerven wiederherstellung und wiedergutmachung.
ES2118253T3 (es) 1992-07-31 1998-09-16 Creative Biomolecules Inc Composicion dietetica enriquecida con morfogen.
DK0661987T3 (da) 1992-09-16 1998-09-14 Creative Biomolecules Inc Morphogeninduceret leverregeneration
CA2147598A1 (en) 1992-11-03 1994-05-11 Hermann Oppermann Op-3-induced morphogenesis
US5372335A (en) 1992-12-18 1994-12-13 Scott H. Yenzer Aerial marker ball and method of placement
WO1994020539A1 (en) 1993-03-04 1994-09-15 Creative Biomolecules, Inc. Method and compositions for recombinant osteogenic protein production
US5631159A (en) 1993-09-22 1997-05-20 Creative Biomolecules, Inc. Lipid-modified serum free media
US5585237A (en) 1993-10-25 1996-12-17 Creative Biomolecules, Inc. Methods and compositions for high protein production from recombinant DNA
DE69431527T2 (de) * 1993-11-15 2003-06-26 Celtrix Pharmaceuticals, Inc. Verwendung von igf-1 und igfbp-3 zur herstellung eines arzneimittels zur behandlung von einer nierenerkrankung
US5525621A (en) * 1994-05-20 1996-06-11 Cytos Pharmaceuticals Llc Imidazole derivatives as protective agents in reperfusion injury and severe inflammatory responses
US5714511A (en) * 1995-07-31 1998-02-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Selective prevention of organ injury in sepsis and shock using selection release of nitric oxide in vulnerable organs
US5723411A (en) * 1995-10-31 1998-03-03 E. I. Du Pont De Nemours And Company Herbicidal pyridazinones
JP4847634B2 (ja) * 1996-03-22 2011-12-28 ストライカー・コーポレーション 中枢神経系の虚血または外傷の機能的回復を増大させる方法
US5820589A (en) * 1996-04-30 1998-10-13 Medtronic, Inc. Implantable non-invasive rate-adjustable pump
US6498142B1 (en) * 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
US5879908A (en) * 1997-04-30 1999-03-09 Smithkline Beecham Corporation CRFG-1a, a target and marker for chronic renal failure
US7147839B2 (en) * 1998-05-29 2006-12-12 Curis, Inc. Methods for evaluating tissue morphogenesis and activity

Also Published As

Publication number Publication date
CA2254954C (en) 2010-01-12
WO1997041881A1 (en) 1997-11-13
US8377878B2 (en) 2013-02-19
US6498142B1 (en) 2002-12-24
DE69723845D1 (de) 2003-09-04
PT914146E (pt) 2005-02-28
WO1997041880A1 (en) 1997-11-13
DE69723845T2 (de) 2004-06-03
JP2012229268A (ja) 2012-11-22
EP0914146B1 (de) 2004-09-29
EP0910400B1 (de) 2003-07-30
US8017580B2 (en) 2011-09-13
US20100291170A1 (en) 2010-11-18
JP5247593B2 (ja) 2013-07-24
DE69730966T2 (de) 2006-02-23
ES2230604T3 (es) 2005-05-01
US20050143304A1 (en) 2005-06-30
US20120004171A1 (en) 2012-01-05
ATE277629T1 (de) 2004-10-15
ATE245997T1 (de) 2003-08-15
JP2000510124A (ja) 2000-08-08
DK0914146T3 (da) 2005-01-31
DE69730966D1 (de) 2004-11-04
US6861404B1 (en) 2005-03-01
EP0914146A1 (de) 1999-05-12
AU2933997A (en) 1997-11-26
JP2000510835A (ja) 2000-08-22
AU2832297A (en) 1997-11-26
JP2009185076A (ja) 2009-08-20
EP0910400A1 (de) 1999-04-28
CA2254953C (en) 2006-09-26
JP4766722B2 (ja) 2011-09-07
PT910400E (pt) 2003-12-31
ES2203803T3 (es) 2004-04-16
CA2254953A1 (en) 1997-11-13
US7524817B2 (en) 2009-04-28
CA2254954A1 (en) 1997-11-13

Similar Documents

Publication Publication Date Title
DK0910400T3 (da) Terapier for kronisk nyresvigt
ATE278414T1 (de) Therapien zur behandlung von akutem nierenversagen
NO970536D0 (no) Behandlingssystem for avgitt blod med skrå reguleringsgrenseflate
HUP9700603A1 (hu) Gyógyászati készítmény véralvadási zavarok kezelésére
IS2925B (is) Ákvörðun á batahorfum sjúklings sem undirgengst meðhöndlun við Alzheimer-sjúkdómi
NO982436D0 (no) Apparat for oppvarming av blod
DK52089D0 (da) Middel til behandling af nyresygdomme
WO2004006756A3 (en) THERAPIES FOR RENAL FAILURE USING INTERFERON-β
DE69726345D1 (de) Apparat zur extrakorporalen Blutbehandlung
DK0751785T3 (da) Kombinationer af thrombolytisk aktive proteiner og antikoagulationsmidler samt anvendelse heraf
DE69825625D1 (de) Aminobiguanide und ihre verwendung zur desinfektion von kontaktlinsen und konservierung von pharmazeutischen zubereitungen
DE59814134D1 (de) Interaktionssystem zur präsentation und entfernung von substanzen
DE69714451D1 (de) Prionbindende proteine und deren verwendungen
WO2004019876A3 (en) Conjoint administration of morphogens and ace inhibitors in treatment of chronic renal failure
HUP9801214A2 (hu) Lecitin-koleszterin acil-transzferázt kifejező rekombináns vírusok és génterápiában való felhasználásuk
ATE361756T1 (de) Insulinartiger-wachstumsfaktorbindungsprotein-4 protease
CY1105117T1 (el) Θepαπειες για τη χρονια νεφρικη ανεπαρκεια χρησιμοποιωντας ανταγωνιστες των ενσωματινων
NZ500216A (en) Beta-amyloid peptide-binding proteins and pharmaceutical use
DE69821227D1 (de) Verwendung von papovavirus kapsid-proteinen zur verabreichung therapeutischen agentien in nervzellen
PT999849E (pt) Utilizacao de lbp no tratamento da septicemia
ATE204169T1 (de) Polyamin-antagonisten enthaltende intraokulare irrigationslösung
DE59609353D1 (de) Mittel zur subkutanen Verabreichung von Protein C
UA29043A (uk) Спосіб визначення коагуляційної активності гемолізаткальцієвої суміші